GlassScriptPhysician profile
Jason C Baker
NPI 1407986144
$427,067.63
in general payments reported to CMS, 2019-2025
13 companies · $140K in 2025
The $140K reported for 2025 was more than what 99% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $12K · 2020: $11K · 2021: $13K · 2022: $15K · 2023: $102K · 2024: $134K · 2025: $140K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $245K · Travel and Lodging: $44K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $44K · Consulting Fee: $37K · Food and Beverage: $6,514.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $244,761.17 |
| Travel and Lodging | $44,212.57 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $43,691.99 |
| Consulting Fee | $36,630.66 |
| Food and Beverage | $6,513.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $291,338.13 | 2019-2025 | |
| Dexcom, INC. | $81,483.38 | 2019-2025 | Dexcom G7 Gss (161), Dexcom Stelo Glucose Biosensor |
| Genzyme Corporation | $24,170.96 | 2025 | |
| Insulet Corporation | $13,306.97 | 2021-2024 | Omnipod |
| Mannkind Corporation | $7,295.02 | 2019 | |
| Medtronic, INC. | $2,345.75 | 2021-2022 | |
| Becton, Dickinson and Company | $2,100.00 | 2019 | |
| Abbott Laboratories | $2,100.00 | 2025 | Freestyle Libre 3 |
| Gi Supply, INC. | $1,400.00 | 2022 | |
| Medtronic Minimed, INC. | $1,240.00 | 2020 | |
| Beta Bionics, INC. | $196.79 | 2024 | Ilet Bionic Pancreas |
| Novo Nordisk INC | $84.50 | 2023 | |
| Cequr Corporation | $6.13 | 2023 | Cequr Simplicity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jason Baker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.